2020
Secondary prevention of cardiovascular disease in China
Lu J, Zhang L, Lu Y, Su M, Li X, Liu J, Zhang H, Nasir K, Masoudi F, Krumholz H, Li J, Zheng X. Secondary prevention of cardiovascular disease in China. Heart 2020, 106: 1349-1356. PMID: 31980439, DOI: 10.1136/heartjnl-2019-315884.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAlcohol DrinkingCardiovascular DiseasesChinaFemaleHealthy LifestyleHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPlatelet Aggregation InhibitorsRisk AssessmentRisk Reduction BehaviorSecondary PreventionSex FactorsSmoking CessationTime FactorsTreatment OutcomeConceptsSecondary prevention drugsIschemic heart diseaseCardiovascular diseasePrevention drugsIschemic strokeSecondary preventionAntiplatelet drugsCardiac Events Million Persons ProjectHistory of IHDMillion Persons ProjectSecondary prevention therapiesPopulation subgroupsMultivariable mixed modelsPublic health programsCommunities of ChinaCurrent smokersCurrent useMedication usePrevention therapyMultivariable analysisChina PatientHeart diseaseCurrent drinkersHealth programsDrugs
2019
P834Secondary prevention medications of cardiovascular diseases in China: findings from China PEACE million persons project
Lu J, Zhang L, Lu Y, Su M, Li X, Li J, Liu J, Zhang H, Nasir K, Masoudi F, Krumholz H, Zheng X. P834Secondary prevention medications of cardiovascular diseases in China: findings from China PEACE million persons project. European Heart Journal 2019, 40: ehz747.0433. DOI: 10.1093/eurheartj/ehz747.0433.Peer-Reviewed Original ResearchSecondary prevention medicationsIschemic heart diseasePrevention medicationsAnti-platelet drugsCardiovascular diseaseMultivariable mixed modelsIschemic strokePopulation subgroupsCardiac Events Million Persons ProjectHistory of IHDPrognosis of CVDMillion Persons ProjectHealth behavior factorsSecondary prevention drugsCause of deathCurrent usePublic health programsPersons ProjectNational Health CommissionCurrent smokersSecondary preventionMedication useMultivariable analysisChina PatientPrevention drugs